key: cord-0699545-fcmm0sx6 authors: Gungor Tuncer, Ozlem; Deymeer, Feza title: Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID‐19 date: 2022-02-09 journal: Muscle Nerve DOI: 10.1002/mus.27497 sha: c50aa634972b7e2ee6541051dba219247e7c575f doc_id: 699545 cord_uid: fcmm0sx6 INTRODUCTION/AIMS: Coronavirus disease‐2019 (COVID‐19) may have a more severe course in patients with myasthenia gravis (MG). We aimed to assess severity of the infection and factors contributing to its severity in a group of MG patients, most of whom were not hospitalized. METHODS: One hundred forty outpatients with MG followed between March 2020 and April 2021 were included in our study. Patients were asked to respond to a brief questionnaire in person, by telemedicine, or through electronic messages. RESULTS: Nineteen patients tested positive for COVID‐19 by polymerase chain reaction. Two were asymptomatic. Of the 17 symptomatic patients, 11 had mild symptoms. They either had no treatment or received antivirals, antibiotics, and anticoagulants. Their myasthenia was well‐controlled before infection and was unaffected by COVID‐19. Three patients with moderate COVID‐19 required hospitalization, but not intensive care, and had full recovery. Three other patients, the oldest in the cohort, had severe disease: One patient with a postsurgery myasthenic exacerbation before the infection needed intensive care without intubation, but recovered completely; two morbidly obese patients with comorbidities required intubation and died. Corticosteroids were increased in four of the six moderate/severely affected patients. Immunosuppressive (IS) agents were generally continued. Hydroxychloroquine (HCQ) for COVID‐19 was used in one patient. DISCUSSION: Most patients had mild COVID‐19 and all but two patients recovered. The design of the study made it possible to capture mild cases. Having well‐controlled MG before infection and absence of comorbidities likely affected the course of the infection favorably. IS did not influence the progression. Methods: One hundred forty outpatients with MG followed between March 2020 and April 2021 were included in our study. Patients were asked to respond to a brief questionnaire in person, by telemedicine, or through electronic messages. Results: Nineteen patients tested positive for COVID-19 by polymerase chain reaction. Two were asymptomatic. Of the 17 symptomatic patients, 11 had mild symptoms. They either had no treatment or received antivirals, antibiotics, and anticoagulants. Their myasthenia was well-controlled before infection and was unaffected by COVID-19. Three patients with moderate COVID-19 required hospitalization, but not intensive care, and had full recovery. Three other patients, the oldest in the cohort, had severe disease: One patient with a postsurgery myasthenic exacerbation before the infection needed intensive care without intubation, but recovered completely; two morbidly obese patients with comorbidities required intubation and died. Corticosteroids were increased in four of the six moderate/severely affected patients. Immunosuppressive (IS) agents were generally continued. Hydroxychloroquine (HCQ) for was used in one patient. Discussion: Most patients had mild COVID-19 and all but two patients recovered. The design of the study made it possible to capture mild cases. Having wellcontrolled MG before infection and absence of comorbidities likely affected the course of the infection favorably. IS did not influence the progression. infection may have a more severe course in MG patients, and that these patients may need more intensive care support. [3] [4] [5] Among 179 patients previously reported, 56% to 100% were hospitalized, and many were intubated. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] It is noteworthy that most of the reported studies were in hospitalized inpatients. Only one study identified patients with COVID-19 by self-report. 4 It is likely that mild cases not hospitalized were missed. Herein we present a questionnaire-based study assessing the severity of the COVID-19 infection and factors contributing to its severity in a defined group of MG patients who were being followed up at our outpatient clinic during the pandemic. All MG patients seen in the outpatient clinic of Memorial Sisli Hospital in person or through telemedicine between March 1, 2020 and April 30, 2021 were considered for the study. In these patients who had fatigable muscle weakness, the diagnosis of MG was made by the presence of one or more of the following: positive anti-acetylcholine receptor antibody (anti-AChR) or anti-muscle-specific kinase antibody (anti-MuSK) test, an unequivocally positive response to anticholinesterases, decrement of over 10% on repetitive nerve stimulation, or abnormal jitter/blocking on single-fiber electromyography. Patients were contacted by electronic message in March to April 2021. The messages were not anonymous, but addressed to the patient. Those seen in person/by telemedicine in the outpatient clinic in February, March, and April of 2021 were not recontacted because they had already been questioned. The first questionnaire aimed to find out which patients had COVID-19 (Table S1 , part A). If the patient had COVID-19, they were recontacted and further questions were asked (Table S1, Mild disease was defined as presence of fever, muscle pain, fatigue, and loss of smell; moderate disease was defined as illness that required hospitalization but not intensive care; and severe disease was defined as illness that required intensive care with or without intubation. Informed consent was obtained from the patients. The study was approved by the institutional review board. Among 180 patients considered for the study, 23 were excluded because they had been seen as a one-time consultation, as they were under the care of another center, and 17 others were excluded because MG was suspected, yet definite diagnosis was not established. The study design is given in the flowchart (Figure 1 It is noteworthy that COVID-19 was mild/asymptomatic in 13 of 19 (68%) affected patients, and full recovery was attained in the majority, including 4 patients with moderate-severe infection. The outpatient-based design of our study likely made it possible to capture milder cases, compared with previous studies 3-5 that evaluated patients admitted to the hospital for COVID-19 infection. In some of the reported patients, there were comorbidities such as obesity, advanced age, and others that could adversely influence progression of the disease. 7 Three patients who had severe disease had major comobidities. Two of them died and one eventually recovered completely. Those with more severe MG, particularly at the onset of infection, were reported to be more likely to have severe Recent data on patients with milder MG supported this observation in that COVID-19 was noted to be more benign in these patients. 6 In line with these observations, a possible reason for the benign course in most of our patients is that myasthenia was well-controlled at the time of COVID-19 in almost all of them, and none had bulbar symptoms. This outcome is not surprising because infections and antibiotics are better tolerated in patients whose myasthenia is in remission or mild. 6 A considerable number of the patients reported were given HCQ, a drug used in the first few months of the pandemic. 23 Moreover, all asymptomatic/mild cases may not have been captured as the patients were not involved in a prospective screening protocol. In conclusion, our study has shown that COVID-19 does not necessarily have a severe course or poor outcome in MG patients. Absence of comorbidities and having well-controlled MG before infection likely affected the course of the infection favorably. As has been reported, IS medications did not seem to influence clinical severity or outcome of COVID-19 in our patients. We thank our patients for their prompt replies and their kind cooperation. None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. Data sharing is not applicable. No new data were generated. Ozlem Gungor Tuncer https://orcid.org/0000-0001-7186-2175 Unraveling the mechanisms involved in motor neuron degeneration in ALS Amyotrophic lateral sclerosis: evaluation and treatment of respiratory impairment The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) Respiratory failure in amyotrophic lateral sclerosis Validity of transcutaneous PCO 2 in monitoring chronic hypoventilation treated with noninvasive ventilation Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: a validation study Spirometric standards for healthy nonsmoking adults Noninvasive ventilation use is associated with better survival in amyotrophic lateral sclerosis Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review COVID-19 and neuromuscular disorders Myasthenia gravis and infectious disease COVID-19-associated risks and effects in myasthenia gravis (CARE-MG) Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network Myasthenia gravis and COVID-19: clinical characteristics and outcomes Myasthenia gravis and COVID-19: a case series and comparison with literature Case series of COVID-19 in patients with myasthenia gravis: a single institution experience COVID-19 in patients with myasthenia gravis Management of patients with generalised myasthenia gravis and COVID-19: four case reports Description of 3 patients with myasthenia gravis and COVID-19 Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a national referral Use of remdesivir in myasthenia gravis and COVID-19 Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19 COVID-19 and generalized myasthenia gravis exacerbation: a case report COVID-19 in muscle-specific kinase myasthenia gravis: a case report COVID-19 in refractory myasthenia gravis---a case report of successful outcome Myasthenic crisis in the setting of coronavirus disease 2019 (COVID-19) Myasthenic crisis in COVID-19 COVID-19 presentation in association with myasthenia gravis: a case report and review of the literature Isolated COVID-19 infection precipitates myasthenia gravis crisis: a case report Myasthenia gravis: recommendations for clinical research standards. Task force of the medical scientific advisory board of the Myasthenia Gravis Foundation of America Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19 The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial Henry Ford COVID-19 management task force. Early short-course corticosteroids in hospitalized patients with COVID-19 HLH across speciality collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression Additional supporting information may be found in the online version of the article at the publisher's website.